Bienaime Jean Jacques
SEC-identified person · CIK 1221590 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Keros Therapeutics, Inc. KROS | Director | filed 2024 - 2026 |
| Immunome Inc. IMNM | Director | filed 2023 - 2026 |
| Incyte Corp INCY | Director | filed 2015 - 2026 |
| Ascendis Pharma A/S ASND | Director | filed 2026 - 2026 |
| Biomarin Pharmaceutical INC BMRN | Director · Chief Executive Officer | filed 2006 - 2024 |
| Vital Therapies INC VTL | Director | filed 2014 - 2018 |
| Intermune INC ITMN | Director | filed 2012 - 2014 |
| Portola Pharmaceuticals INC PTLA | Director | filed 2013 - 2014 |
| Neurogesx Inc NGSX | Director | filed 2007 - 2012 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.